as of 01-16-2026 3:38pm EST
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 3.9B | IPO Year: | 2025 |
| Target Price: | $137.83 | AVG Volume (30 days): | 259.9K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $80.51 - $138.70 | Next Earning Date: | 12-09-2025 |
| Revenue: | $254,136,000 | Revenue Growth: | 254.30% |
| Revenue Growth (this year): | 98.01% | Revenue Growth (next year): | 35.84% |
See how BLLN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "BLLN BillionToOne Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.